Cytyc Corp. 's recent $160 million cash purchase of Proxima Therapeutics Inc. , a brachytherapy company with a device to treat breast cancer [See Deal], follows its acquisition last year of Novacept Inc. , a manufacturer of a minimally invasive endometrial ablation device to treat excessive menstrual bleeding, for $325 million [See Deal]. Three years earlier, Cytyc had acquired, for $174 million, Pro-Duct Health, developer of a new test to assess the breast cancer risk of an at-risk patient [See Deal]. In November 2004, Cytyc also made an equity investment in Valeo Medical Inc. , developer of a noninvasive endometriosis diagnostic [See Deal].
Cytyc still gets 84% of its $393 million in annual revenues from its ThinPrep cervical cancer testing product line, and, having in 2002 been blocked by the Federal Trade Commission...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?